Chemed (CHE) is trading higher as the market looks ahead to the company’s first-quarter 2026 earnings report due after the NYSE close on Thursday, April 23, 2026. With the print imminent, traders are positioning around the potential for updated commentary on VITAS operating momentum and any evidence that Roto-Rooter’s profitability trends are improving after the prior quarter’s disappointment.

Sentiment has been fragile following a weaker fourth quarter and a subsequent reset in confidence, leaving the stock reacting more sharply to incremental data points. The key swing factors are whether VITAS can sustain healthy volume and pricing dynamics and whether Roto-Rooter can curb write-offs and protect margins as the business works through a choppier demand and cost backdrop.

In early April, Chemed’s Roto-Rooter subsidiary completed purchases of the franchise territories and assets in San Francisco, California and Fort Worth, Texas, expanding company-owned coverage in two large metro markets. Separately, Chemed recently put in place an amended and restated five-year revolving credit facility sized at $450 million, giving it additional financial flexibility.

Beyond the headline EPS and revenue, investors will focus on VITAS average daily census, admissions/discharges, and any signals around reimbursement and Medicare cap dynamics, plus Roto-Rooter revenue growth and margin trajectory. Management is also expected to address full-year 2026 outlook and whether the company remains on track for a stronger back half of the year, with follow-up commentary likely to shape the stock’s next move.